Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Cited by (1,024)

Items 601–700 of 1,024

1. Adiponectin
   Ling Tao, Yajing Wang, Erhe Gao, Hangxiang Zhang, Yuexing Yuan, Wayne Bond Lau, Lawrence Chan, Walter J. Koch, Xin L. Ma · 2009 · Circulation Research
2. Disruption of endothelial peroxisome proliferator-activated receptor-γ reduces vascular nitric oxide production
   Jennifer Kleinhenz, Dean J. Kleinhenz, Shaojin You, Jeffrey D. Ritzenthaler, Jason M. Hansen, David R. Archer, Roy L. Sutliff, C. Michael Hart · 2009 · American Journal of Physiology-Heart and Circulatory Physiology
3. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
   Marian Sue Kirkman, Hussain Mahmud, Mary T. Korytkowski · 2018 · Endocrinology and Metabolism Clinics of North America
4. Rosiglitazone Stimulates Nitric Oxide Synthesis in Human Aortic Endothelial Cells via AMP-activated Protein Kinase*
   James G. Boyle, Pamela J. Logan, Marie‐Ann Ewart, James A Reihill, Stuart A. Ritchie, John Connell, Stephen J. Cleland, Ian P. Salt · 2008 · Journal of Biological Chemistry
5. Glycemic Management in ESRD and Earlier Stages of CKD
   Mark E. Williams, Rajesh Garg · 2014 · American Journal of Kidney Diseases
6. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
   Y. Miyazaki, Ralph A. DeFronzo · 2008 · Diabetes Obesity and Metabolism
7. Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting?
   Melissa A. Fischer, Mary Ellen Keough, Joann L. Baril, Laura Saccoccio, Kathleen M. Mazor, Elissa Ladd, Ann Von Worley, Jerry H. Gurwitz · 2009 · Journal of General Internal Medicine
8. Falsification Testing of Instrumental Variables Methods for Comparative Effectiveness Research
   Steven D. Pizer · 2015 · Health Services Research
9. Does reversal of oxidative stress and inflammation provide vascular protection?
   Kwang Kon Koh, P. C. Oh, Michael J. Quon · 2008 · Cardiovascular Research
10. PPARδ Is Required for Exercise to Attenuate Endoplasmic Reticulum Stress and Endothelial Dysfunction in Diabetic Mice
    Wai San Cheang, Wing Tak Wong, Lei Zhao, Jian Xu, Li Wang, Chi Wai Lau, Zhen‐Yu Chen, Ronald C.W., Aimin Xu, Nanping Wang et al. · 2016 · Diabetes
11. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists
    Mohamed K. Ibrahim, Ibrahim H. Eissa, Mohamed S. Alesawy, Ahmed M. Metwaly, Mohamed M. Radwan, Mahmoud A. ElSohly · 2017 · Bioorganic & Medicinal Chemistry
12. Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation: A Randomized, Placebo-Controlled Clinical Trial
    Werzowa, Johannes, Hecking, Manfred, Haidinger, Michael, Lechner, Felix, Döller, Dominik, Pacini, Giovanni, Stemer, Gunar, Pleiner, Johannes, Frantal, Sophie, Säemann, Marcus D. · 2013 · Transplantation
13. Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform
    Sashi Nadanaciva, Payal Rana, Gyda C. Beeson, Denise Chen, David A. Ferrick, Craig Beeson, Yvonne Will · 2012 · Journal of Bioenergetics and Biomembranes
14. Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011
    Takahide Kohro, Tsutomu Yamazaki, Hiroki Sato, Kenji Harada, Kazuhiko Ohe, Issei Komuro, Ryozo Nagai · 2013 · International Heart Journal
15. Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007–2013 in Catalonia: a population-based study
    Manel Mata‐Cases, Josep Franch‐Nadal, Jordi Real, Dı́dac Mauricio · 2016 · BMJ Open
16. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach
    Enrico D’Aniello, Tariq G. Fellous, Fabio Arturo Iannotti, Alessandra Gentile, Marco Allarà, Francesca Balestrieri, Roy Gray, Pietro Amodeo, Rosa Maria Vitale, Vincenzo Di Marzo · 2019 · Biochimica et Biophysica Acta (BBA) - General Subjects
17. Generating comparative evidence on new drugs and devices after approval
    Andrea Cipriani, John P. A. Ioannidis, Peter Malcolm Rothwell, Paul Glasziou, Tianjing Li, Adrian F. Hernandez, Anneka Tomlinson, Robert John Simes, Huseyin Naci · 2020 · The Lancet
18. Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
    Kevin Dean Niswender · 2009 · Diabetes Obesity and Metabolism
19. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
    Giugliano, Dario, Sportiello, Liberata, Capuano, Annalisa, Maiorino, Mariaida, Rossi, Francesco, Esposito, Katherine · 2013 · Drug Design, Development and Therapy
20. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
    Kiwon Ban, Sonya Hui, Daniel J. Drucker, Mansoor Husain · 2009 · Journal of the American Society of Hypertension
21. Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
    Pieter Martens, Chantal Mathieu, Frederik Hendrik Verbrugge · 2017 · Current Treatment Options in Cardiovascular Medicine
22. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis
    Albert J. Czaja · 2014 · Alimentary Pharmacology & Therapeutics
23. Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy
    Lucy Q. Shen · 2008 · Archives of Ophthalmology
24. Type 2 Diabetes Prevention: A Review
    Leena A. Ahmad, Jill P. Crandall · 2010 · Clinical Diabetes
25. Diabetes mellitus: new drugs for a new epidemic
    Grainne Nicholson, G.M. Hall · 2011 · British Journal of Anaesthesia
26. Haematoma scavenging in intracerebral haemorrhage: from mechanisms to the clinic
    Gaiqing Wang, Li Wang, Xin‐gang Sun, Jiping Tang · 2017 · Journal of Cellular and Molecular Medicine
27. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: Potential utility in treatment of diabetes and heart disease
    Dana S. Hutchinson, Roger J. Summers, Tore Bengtsson · 2008 · Pharmacology & Therapeutics
28. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
    Lance L. Stein, Mamie H. Dong, Rohit Seth Loomba · 2009 · Advances in Therapy
29. Novel Diabetes Drugs and the Cardiovascular Specialist
    Naveed A. Sattar, Mark Colquhoun Petrie, Bernard Zinman, James L. Januzzi · 2017 · Journal of the American College of Cardiology
30. Diabetes and bone
    Katrine Hygum, Jakob Starup‐Linde, Bente Lomholt Langdahl · 2019 · Osteoporosis and Sarcopenia
31. Treating type 2 diabetes: how safe are current therapeutic agents?
    Jacques Philippé, D. Raccah · 2009 · International Journal of Clinical Practice
32. Current management of diabetes mellitus and future directions in care
    Sudesna Chatterjee, Melanie Jane Davies · 2015 · Postgraduate Medical Journal
33. The role of peroxisome proliferator‐activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus
    D. Gupta, Tatsuyoshi Kono, Carmella Evans‐Molina · 2010 · Diabetes Obesity and Metabolism
34. The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer
    Linda Slanec Higgins, Christos Socrates Mantzoros · 2008 · PPAR Research
35. The changing nature of communication and regulation of risk in Europe
    Ragnar Ernst Löfstedt, Frederic Emmanuel Bouder, Jamie K. Wardman, Sweta Chakraborty · 2011 · Journal of Risk Research
36. The 'forgotten' bile acid sequestrants: is now a good time to remember?
    Bays, Harold E, Goldberg, Ronald B · 2007 · American Journal of Therapeutics
37. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
    Paneni, Francesco, Lüscher, Thomas F. · 2017 · The American Journal of Cardiology
38. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
    Julio Rosenstock, Vlado Perkovic, John Hunter Alexander, Mark Emmanuel Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra et al. · 2018 · Cardiovascular Diabetology
39. Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey
    Phuc Le, Alexander M. Chaitoff, Anita D. Misra‐Hebert, Wen Ye, William H. Herman, Michael B. Rothberg · 2020 · Diabetes Care
40. Key Characteristics of Cardiovascular Toxicants
    Lars Lind, Jesus A. Araujo, Aaron Barchowsky, Scott M. Belcher, Brian R. Berridge, Nipavan Chiamvimonvat, Weihsueh A. Chiu, Vincent J. Cogliano, Sarah Elmore, Aimen K. Farraj et al. · 2021 · Environmental Health Perspectives
41. Design of a Prospective, Dose-Escalation Study Evaluating the Safety of Pioglitazone for Hematoma Resolution in Intracerebral Hemorrhage (SHRINC)
    Nicole R. Gonzales, Jharna Nitin Shah, Navdeep S Sangha, Lenis Sosa, Rebecca Martinez, Loren F Shen, Mallikarjunarao Kasam, Miriam M. Morales, Md. Monir Hossain, Andrew D. Barreto et al. · 2012 · International Journal of Stroke
42. Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records
    John S. Brownstein, Shawn N. Murphy, Allison B. Goldfine, Richard William Grant, Margarita Sordo, Vivian S. Gainer, Judith Colecchi, A. K. Dubey, David M. Nathan, JOHN P. GLASER et al. · 2009 · Diabetes Care
43. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
    Bo Åhrén · 2008 · Vascular Health and Risk Management
44. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
    Garg, Vinay, Verma, Subodh, Connelly, Kim · 2019 · Progress in Cardiovascular Diseases
45. Therapy of nonalcoholic fatty liver disease: current status.
    Marko Duvnjak, Vedran Tomašić, Marija Gomerčić, Lea Smircic Duvnjak, Neven Baršić, Ivan Lerotić · 2009 · PubMed
46. PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
    Veronica Vella, Maria Luisa Nicolosi, Stefania Giuliano, Maria Bellomo, Antonino Belfiore, Roberta Malaguarnera · 2017 · Frontiers in Endocrinology
47. Cardiovascular outcome trials of glucose-lowering medications: an update
    Philip D. Home · 2019 · Diabetologia
48. CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4‐Fatty Acid β‐Oxidation Pathway
    Hongquan Li, Junjiao Song, Yifei He, Yizhe Liu, Zhen Liu, Weili Sun, Weiguo Hu, Qun‐Ying Lei, Xin Hu, Zhiao Chen et al. · 2022 · Advanced Science
49. Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages
    Töröcsik, Dániel, Szanto, Attila, Nagy, László · 2009 · Molecular Aspects of Medicine
50. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management
    Absalon Gutierrez, Ashok Balasubramanyam · 2011 · Endocrine
51. Sphingolipids, Lipotoxic Cardiomyopathy, and Cardiac Failure
    Tae‐Sik Park, Ira J. Goldberg · 2012 · Heart Failure Clinics
52. Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice
    Lichan Tao, Sutong Shen, Siyi Fu, Hongyi Fang, Xiuzhi Wang, Saumya Das, Joost P. G. Sluijter, Anthony Rosenzweig, Yonglan Zhou, Xiangqing Kong et al. · 2015 · Scientific Reports
53. Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease
    Weilin Liu, Dicky Struik, Vera J. M. Nies, Angelika Jurdzinski, Liesbeth Harkema, Alain de Bruin, Henkjan J. Verkade, Michael Downes, Ronald M. Evans, Tim van Zutphen et al. · 2016 · Proceedings of the National Academy of Sciences
54. Managing Type 2 Diabetes: Going Beyond Glycemic Control
    MARK W. STOLAR, Byron J. Hoogwerf, Patrick J. Boyle, Stephen M Gorshow, Dirk O Wales · 2008 · Journal of Managed Care Pharmacy
55. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
    Charles M. Gerrits, Mondira Bhattacharya, Shivaji R. Manthena, Robert W. Baran, Alfonso Perez, Stuart Kupfer · 2007 · Pharmacoepidemiology and Drug Safety
56. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus.
    Avogaro, Angelo, Kreutzenberg, Saula Vigili de, Fadini, GianPaolo · 2008 · Diabetes Research and Clinical Practice
57. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
    Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas L. Seck, Sanjay Dhanji Patel, Hans‐Juergen Woerle, Odd Erik Johansen · 2015 · Cardiovascular Diabetology
58. Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis
    Jennifer Melissa Kaplan, Marchele Nowell, Ranjit S. Chima, Basilia Zingarelli · 2013 · Innate Immunity
59. PPARs and Angiogenesis—Implications in Pathology
    Nicole Wagner, Kay‐Dietrich Wagner · 2020 · International Journal of Molecular Sciences
60. Exercise-associated generation of PPARγ ligands activates PPARγ signaling events and upregulates genes related to lipid metabolism
    A. W. Thomas, N. A. Davies, Hannah Jayne Moir, Laura J. Watkeys, José S. Ruffino, SA Isa, Lee Butcher, Michael G. Hughes, Keith Morris, R Webb · 2011 · Journal of Applied Physiology
61. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
    Rhona Johnston, Olalekan Abdulrahman Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill L Colquitt, Bee Kang Tan, Andrew J Clegg, Saran Shantikumar, Rachel A. Court et al. · 2017 · Health Technology Assessment
62. Deciphering the decline of metabolic elasticity in aging and obesity
    Zhou, Qiuzhong, Yu, Lexiang, Cook, Joshua R., Qiang, Li, Sun, Lei · 2023 · Cell Metabolism
63. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications
    Jason B. Lindsey, Francesco Cipollone, Shuaib M. Abdullah, Darren K. McGuire · 2009 · Diabetes and Vascular Disease Research
64. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
    Naomi Franziska Lange, Vanessa Graf, Cyrielle Caussy, Jean‐François Dufour · 2022 · International Journal of Molecular Sciences
65. Redefining Quality — Implications of Recent Clinical Trials
    Harlan M. Krumholz, Thomas Ho-yin Lee · 2008 · New England Journal of Medicine
66. Peroxisome Proliferator-Activated Receptor .GAMMA. and Cardiovascular Diseases
    Hiroyuki Takano, Issei Komuro · 2009 · Circulation Journal
67. Meta‐analysis of clinical trials with rare events
    Dankmar Böhning, Kalliopi Mylona, Alan Kimber · 2015 · Biometrical Journal
68. Improvements in the Management of Diabetic Nephropathy
    Evangelia C. Dounousi, Αnila Duni, Konstantinos Leivaditis, Vasilios Vaios, Theodoros Eleftheriadis, Vassilios Liakopoulos · 2015 · The Review of Diabetic Studies
69. An update on DPP-4 inhibitors in the management of type 2 diabetes
    Avivit Cahn, Simona Cernea, Itamar Raz · 2016 · Expert Opinion on Emerging Drugs
70. Uncoupling protein 3 deficiency impairs myocardial fatty acid oxidation and contractile recovery following ischemia/reperfusion
    Kristin Shirey Edwards, Sadia Ashraf, Tyler M. Lomax, Jessica M. Wiseman, Michael E. Hall, Fábio Nelson Gava, John Edward Hall, Jonathan P. Hosler, Romain Harmancey · 2018 · Basic Research in Cardiology
71. Generating comparative evidence on new drugs and devices before approval
    Huseyin Naci, Maximilian Salcher‐Konrad, Aaron Seth Kesselheim, Beate Wieseler, Lise Rochaix, Rita F. Redberg, Georgia Salanti, Emily Jackson, Sarah E. Garner, T. Scott Stroup et al. · 2020 · The Lancet
72. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
    Adam J. Nelson, Neha Jadeja Pagidipati, Vanita R. Aroda, Matthew Aaron Cavender, Jennifer B. Green, Renato D. Lópes, Hussein R. Al‐Khalidi, Tanya Gaynor, Lisa A. Kaltenbach, Julienne K. Kirk et al. · 2021 · Circulation
73. The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
    Mahmoud M Mansour · 2014 · Progress in molecular biology and translational science
74. Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
    Martijn C.G.J. Brouwers, Chantal Jacobs, Aalt Bast, Coen D.A. Stehouwer, Nicolaas C. Schaper · 2015 · Trends in Molecular Medicine
75. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure
    Erland Erdmann, Robert G. Wilcox · 2007 · European Heart Journal
76. Saroglitazar for the treatment of dyslipidemia in diabetic patients
    Shashank Joshi · 2015 · Expert Opinion on Pharmacotherapy
77. General aspects of muscle glucose uptake
    Rafael de Oliveira Alvim, MARCEL R. CHEUHEN, SILMARA R. MACHADO, André Gustavo Pires de Sousa, PAULO C.J.L. SANTOS · 2015 · Anais da Academia Brasileira de Ciências
78. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
    James G. Boyle, Rachel Livingstone, John R. Petrie · 2018 · Clinical Science
79. Therapeutic medications against diabetes: What we have and what we expect
    Cheng Hu, Weiping Jia · 2018 · Advanced Drug Delivery Reviews
80. Anti-Inflammatory Nutrition as a Pharmacological Approach to Treat Obesity
    Barry Sears, Camillo Ricordi · 2010 · Journal of Obesity
81. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
    Michael E. Cobble, Robert C. Frederich · 2012 · Cardiovascular Diabetology
82. SGLT2 inhibitors in the management of type 2 diabetes
    R. P. Monica Reddy, Silvio E. Inzucchi · 2016 · Endocrine
83. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    Zeqing Zhang, Xi Chen, Puhan Lu, Jianhua Zhang, Yongping Xu, Wentao He, Mengni Li, Shujun Zhang, Jing Jia, Shiying Shao et al. · 2017 · Cardiovascular Diabetology
84. Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center
    Takashi Ando, Nobuhiro Ooba, Mayumi Mochizuki, Daisuke Koide, Koichi Kimura, Seitetz L. Lee, Soko Setoguchi, Kiyoshi Kubota · 2018 · BMC Health Services Research
85. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
    Xunzhe Yin, Xiangyu Guo, Zuojia Liu, Jin Wang · 2023 · International Journal of Molecular Sciences
86. Progress and Deficiencies in the Registration of Clinical Trials
    Alastair J.J. Wood · 2009 · New England Journal of Medicine
87. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
    Nikolaos P. E. Kadoglou, H. Tsanikidis, Alkistis Kapelouzou, Ioannis S. Vrabas, Ioulia Vitta, Panayotis E. Karayannacos, Christos D. Liapis, Nikolaos Sailer · 2009 · Metabolism
88. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes
    Francesco Di Pierro, Pietro Putignano, Luca Montesi, Simona Moscatiello, Giulio Marchesini, Nicola Villanova · 2013 · Clinical Pharmacology Advances and Applications
89. Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: Methods for the absolute risk difference and relative risk
    Haitao Chu, Lei Nie, Yong Chen, Yi Huang, Wei Sun · 2010 · Statistical Methods in Medical Research
90. Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator–Activated Receptor γ
    Raphael A. Nemenoff, Amy M. Meyer, Tyler M. Hudish, Anthony B. Mozer, Amy Snee, Shuh Narumiya, Robert S. Stearman, Robert A. Winn, Mary C.M. Weiser‐Evans, Mark W. Geraci et al. · 2008 · Cancer Prevention Research
91. Nuclear Receptor-Coregulator Interaction Profiling Identifies TRIP3 as a Novel Peroxisome Proliferator-activated Receptor γ Cofactor
    Arjen Koppen, René Houtman, Dirk Pijnenburg, Ellen H. Jeninga, Rob Ruijtenbeek, Eric Kalkhoven · 2009 · Molecular & Cellular Proteomics
92. Addressing insulin resistance in Type 1 diabetes
    T. T. L. Pang, Parth Narendran · 2008 · Diabetic Medicine
93. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
    A. S. Abdelmoneim, Dean T. Eurich, Peter E. Light, Peter Alexander Senior, John M. Seubert, Mark J. Makowsky, Scot H. Simpson · 2015 · Diabetes Obesity and Metabolism
94. Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
    Philip Noel Newsome, Rohit Loomba · 2025 · Journal of Clinical Investigation
95. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
    Lisa B. VanWagner, Mary Eugenia Rinella · 2011 · Therapeutic Advances in Gastroenterology
96. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses
    Jun Wei, Hongyan Zhu, Kazuhiro Komura, Gabriel Lord, Michal Tomčík, Wenxia Wang, Sruthi Doniparthi, Zenshiro Tamaki, Monique Hinchcliff, Joerg H W Distler et al. · 2013 · Annals of the Rheumatic Diseases
97. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases
    Jichun Yang, Yunfeng Zhou, Youfei Guan · 2011 · Current Opinion in Nephrology & Hypertension
98. Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes
    Rui Liu, Haitao Wang, Baofeng Xu, Wenliang Chen, Ekaterina Turlova, Nan Dong, Christopher L. F. Sun, Yangqingqin Lu, Hanhui Fu, Ranran Shi et al. · 2016 · Diabetes
99. Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm
    Timothy Silleck Bailey · 2013 · The American Journal of Medicine
100. Therapeutic Trials in Nonalcoholic Steatohepatitis
     Vlad Ratziu, Stephen Hugh Caldwell, Brent A. Neuschwander‐Tetri · 2010 · Hepatology